Targeted Tumor Therapy with “Magnetic Drug Targeting”: Therapeutic Efficacy of Ferrofluid Bound Mitoxantrone

Magnetic Colloids As Drug Vehicles

“…Another estimation116 of the magnetic field required to accomplish the condition F mag > F hyd for most magnetic carriers suggests that the flux densities at the target site must be of the order of 0.2 T with field gradients of approximately 8 T/m for femoral arteries and greater than 100 T/m for carotid arteries. For example, in an in vivo experiment for treating cancer in rabbit models (VX2 squamous cell carcinoma in hind limb; intra‐arterial injection in femoral artery; mitoxantrone bound to starch‐coated magnetite particles with hydrodynamic diameter of 100 nm) the field conditions were: maximum B = 1.7 T; field gradient 70 T/m 62…”

In vitro study of deep capture of paramagnetic particle for targeting therapeutics

“…Furthermore, MDT improves the effectiveness of the treatment by reducing the total dose needed to reach the therapeutic benefit, exposure of healthy tissue to the treatment and side effects [8,9]. In recent studies the magnet or general electromagnet [10][11][12][13] has been used to produce the magnetic field, which has some inherent limitations for the magnetic flux density is maximal at the magnet pole face and cannot be focused at a distance from the magnet [14]. Therefore, the application of the magnetic drug targeting has been limited to the superficial tumor, such as cutaneous carcinoma, mammary cancer.…”

Magnetic nanoparticle imaging by means of minimum norm estimates from remanence measurements

“…These properties give them a high potential for use in both medical diagnostics and therapy [15,19,22]. They are used for magnetic hyperthermia [14,17], magnetic drug targeting [2,6], cell separation [3], as labels in immunoassays [8,30] and as contrast agents in MRI [5,26]. The quantitative determination of the nanoparticle distribution over large tissue areas remains a challenge.…”